Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection

Table 3

Use of RLAI.

Variable	𝑁	Mean
Reasons for initiation to RLAI* (%)
Adverse event: weight gain	177	3 (1.7%)
Adverse event: extrapyramidal symptoms	177	14 (7.9%)
Adverse event: other	177	11 (6.2%)
Lack of efficacy	177	61 (34.5%)
Relapse	177	47 (26.6%)
Patient choice	177	26 (14.7%)
Noncompliance	177	112 (63.3%)
Unknown	177	0
Duration of RLAI use (days)	177	485.5 (SD 287.4); range 0–936
RLAI persistence (proportion of patients known to continue therapy during)
at least 6 months	175^†	134 (76.6%)
at least 12 months	172^†	122 (70.9%)
at least 18 months	128^†	87 (68.0%)
at least 24 months	68^†	45 (66.2%)
Reasons for stopping RLAI* (%)
Adverse event: weight gain	66	2 (3.0%)
Adverse event: extrapyramidal	66	3 (4.5%)
Adverse event: other	66	10 (15.2%)
Lack of efficacy	66	23 (34.8%)
Relapse	66	2 (3.0%)
Patient choice	66	22 (33.3%)
Noncompliance	66	23 (34.8%)
Unknown	66	0

*Multiple answers were allowed. ^†Reduced sample size reflects follow-up durations.